Low Float (NYSE American: NSRX) Surges Up Our Watchlist Behind 5 Key Potential Catalysts

Catch a whiff of Tuesday's profile?

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored Low Float (NYSE American: NSRX) Surges Up Our Watchlist Behind 5 Key Potential Catalysts *Get Our Updates Faster—Tap Here To Receive SMS Alerts* March 25th Greetings, Friend! Catch a whiff of Tuesday's profile? All that low float idea did was rumble $1.00+ intraday from an open of $6.33 to a high of $7.43. That surge resulted in a pop of approximately 17% intraday. But let's get dialed in for the main event... In a market poised to double over the coming decade, one innovative player is redefining how life-saving treatments reach patients. With the global epinephrine market projected to grow from $2.66Bn in 2026 to $5.46Bn by 2034—an impressive 9.41% compounded annual growth rate—this under-the-radar company is pursuing a faster, more intuitive approach to emergency response. Its latest strides in intranasal technology are setting the stage for a new standard in speed, accessibility, and patient-friendly medical solutions. And with a low float of fewer than 4Mn shares and a massive analyst $22 target, this NYSE American profile has quickly risen to my top watchlist spot: Nasus Pharma Ltd. (NYSE American: NSRX) Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’ intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. The Nasax® proprietary powder formulation for intranasal delivery consists of uniform-sized spherical API and a carrier approved for inhalation. The technology enables a rapid and precise delivery of the drug to the bloodstream and brain. Stability data demonstrate the potential for a longer shelf life and other advantages versus liquid formulations. NS002 Epinephrine: Next-Generation Treatment for Anaphylaxis NS002 is Nasus Pharma’s epinephrine intranasal powder candidate in development for the treatment of anaphylaxis. With phase 2 data demonstrating faster and higher absorption than the EpiPen®, NS002 is poised to transform a market underserved by the current bulky needle-based autoinjectors and nasal sprays with a short shelf life. NS002 Designed to Address the Limitations of Intramuscular Epinephrine NS002: Summary of Phase 2 Results: NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors NS002 reached the hemodynamic therapeutic plasma threshold faster than the EpiPen® Maximum epinephrine absorption (tmax) achieved significantly faster compared to EpiPen® Nasax powder was well tolerated with transient mild symptoms No findings at the nasal examinations No serious adverse events Pipeline: Robust Asset Pipeline Setting Up Potential for Long Term Growth Nasus Pharma is advancing a portfolio of powder-based intranasal therapies designed to address life-threatening emergencies.  Their proprietary Nasax® platform delivers rapid, reliable absorption and predictable pharmacokinetics, creating opportunities across multiple acute indications. Find Sources And More: NSRX Website. NSRX Presentation. ----- 5 Potential Catalysts Put (NYSE American: NSRX) In The Spotlight Wednesday 1.) NSRX Has A Really Low Float (The Potential For Heightened Volatility May Be Substantial). Sporting a float of roughly 3.89Mn shares, according to Yahoo Finance, the potential for heightened volatility appearing quickly should not be dismissed. 2.) Nasus Pharma Accelerates Progress With Breakthrough Innovation (Announces Positive Top Line Data). Nasus Pharma Ltd. announced highly positive Phase 2 top line results for its intranasal epinephrine formulation, NS002, showing faster and more efficient epinephrine delivery than EpiPen®.  NS002 reached the therapeutic threshold in just 1.69 minutes versus 3.42 minutes for EpiPen® and achieved higher overall absorption in the critical early minutes. The product maintained a strong safety profile with no serious adverse events. Powered by the proprietary Nasax® powder platform, NS002 is positioned as a convenient, needle-free breakthrough. A pivotal study is planned for Q4 2026. 3.) An Analyst Provides A Massive $22 Price Target (Over 750% Potential Upside). A Laidlaw & Company analyst has tagged NSRX with a significant $22 target. That target provides NSRX with a potential upside of 750+% from its closing valuation Tuesday. Here are some highlights from the report: We are initiating coverage on Nasus Pharma with a ... 12-month $22 price target. NSRX is a mid-clinical stage biotech/specialty pharma company focusing on the development of NS-002, a well differentiated powder-based intranasal anaphylaxis treatment. The recently reported NS-002 in anaphylaxis Phase II study showed robust outcomes in all measured metrics, especially the critical ones of Cmax, Tmax, T100pg/ml and percentage of patients with time taken to reach 100pg when compared with EpiPen. 4.) A Research Company Points Its Focus Towards NSRX With An Electrifying Report. In March, Zacks SCR, shared a fully-detailed report on (NYSE American: NSRX). Important recent and future milestones from the report: NP007 Phase II Interim Readout – March 2026 NS002 Investigation New Drug (IND) submission – 3Q:26 Target presentation at allergy and anaphylaxis conferences (AAAAI & ACAAI) – 2026/2027 Publication of data in a respected journal – 2026/2027 Launch NS002 pivotal study – 4Q:26 Pivotal study readout – 1Q:27 New Drug Application (NDA) submission to the FDA – 2Q:27 5.) Nasus Pharma Strengthens Growth And Innovation Through Transformative 2025 Achievements. Nasus Pharma's CEO Dan Teleman’s 2025 shareholder letter highlighted a breakthrough year for Nasus Pharma. The company made major progress developing NS002, its intranasal epinephrine powder, following successful early clinical trials and a $10Mn IPO. Partnerships with Aptar enhance regulatory and manufacturing readiness, while Health Canada authorized NS002’s Phase 2 study. Nasus plans multiple milestones in 2026, including its recently announced positive Phase 2 topline results. These advancements underline Nasus Pharma’s strong momentum toward market introduction of life-saving, user-friendly nasal treatments and expansion of its innovative Nasax-based pipeline. ----- Coverage is initiated on Nasus Pharma Ltd. (NYSE American: NSRX). Keep your eyes peeled for updates coming soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 03/24/2026 and ending on 03/25/2026 to publicly disseminate information about (NSRX:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC eight thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid sixteen thousand USD ("Funds"). Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NSRX:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/nsrx-sf03l/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice